Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD.

Asger R Bihlet, Morten A Karsdal, Anne-Christine Bay-Jensen, Simon Read, Jacob Hull Kristensen, Jannie Marie Bülow Sand, Diana Julie Leeming, Jeppe Ragnar Andersen, Peter Lange, Jørgen Vestbo

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Despite massive investments in the development of novel treatments for heterogeneous diseases such as COPD, the resources spent have only benefited a fraction of the population treated. Personalized health care to guide selection of a suitable patient population already in the clinical development of new compounds could offer a solution. This review discusses past successes and failures in drug development and biomarker research in COPD, describes research in COPD phenotypes and the required characteristics of a suitable biomarker for identifying patients at higher risk of progression, and examines the role of extracellular matrix proteins found to be upregulated in COPD. Novel biomarkers of connective tissue remodeling that may provide added value for a personalized approach by detecting subgroups of patients with active disease suitable for pharmacologic intervention are discussed.
    Original languageEnglish
    JournalChest
    Volume148
    Issue number1
    DOIs
    Publication statusPublished - 1 Jul 2015

    Fingerprint

    Dive into the research topics of 'Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD.'. Together they form a unique fingerprint.

    Cite this